Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects

Clinical Drug Investigation

Volumn 31, Issue 9, 2011, Pages 619-630

  Boulton, David W ^a   Smith, Charles H ^b   Li, L ^a   Huang, Jian ^b   Tang, Angela ^a   LaCreta, Frank P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Antihyperglycaemics; Bioequivalence; CD26 antigen inhibitors; Fixed combinations; Metformin; Saxagliptin; Saxagliptinmetformin; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; METFORMIN PLUS SAXAGLIPTIN; SAXAGLIPTIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FOOD DRUG INTERACTION; FOOD INTAKE; HEADACHE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ADAMANTANE; ADMINISTRATION, ORAL; ADULT; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; TABLETS; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 80051523643     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11590290-000000000-00000     Document Type: Article

References (12)

1. Monnier L, Benichou M, Charra-Ebrard S, et al. An overview of the rationale for pharmacological strategies in type 2 diabetes: from the evidence to new perspectives. Diabetes Metab 2005 Apr; 31 (2): 101-9 (Pubitemid 40577192)
2. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011 Jan; 13(1): 7-18
3. Kirby M, Yu DM, O'Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2009 Sep 28; 118 (1): 31-41
4. United States Prescribing Information for Onglyza [online]. Available from URL: pi-onglyza.pdf [Accessed 2011 Feb 1]
5. United States Prescribing Information for Glucophage/Glucophage XR [online]. Available from URL: http://packageinserts.bms.com/pi/pi-glucophage.pdf [Accessed 2009 Jan 1]
6. Hinke SA, Kuhn-Wache K, Hoffmann T, et al. Metformin effects on dipeptidylpeptidase IV degradation of glucagonlike peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-8 (Pubitemid 34694333)
7. Lenhard JM, Croom DK, Minnick DT. Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. Biochem Biophys Res Commun 2004; 324: 92-7 (Pubitemid 39311464)
8. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-55
9. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-22
10. Patel CG, Komoroski BJ, Brenner E, et al. No meaningful pharmacokinetic drug-drug interaction between saxagliptin and metformin in healthy subjects [abstract 213]. Presented at the American College of Clinical Pharmacy Annual Meeting, Denver (CO), October 2007
11. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extendedrelease formulation. Clin Ther 2003 Feb; 25 (2): 515-29 (Pubitemid 36286917)
12. Data on file, Bristol-Myers Squibb Company, 2011